Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Artiva Biotherapeutics Readies for the Next Phase of Growth with the Appointment of Neha Krishnamohan as CFO and EVP, Corporate Development and Promotion of Jennifer Bush to Chief Operating Officer
Read Article
News
2024
2023
Archive
Search news articles
June 10, 2022
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
June 10, 2022
Inipharm Appoints Chuhan Chung, M.D, as Chief Medical Officer to Advance HSD17B13 Program into the Clinic
June 6, 2022
Artiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer
June 1, 2022
CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease
June 1, 2022
Nouscom to Present Full Phase 1 Data of NOUS-209, an “Off-The-Shelf” Neoantigen Cancer Immunotherapy for the Treatment of DMMR/MSI-H Solid Tumors, at ASCO 2022
May 23, 2022
Nouscom Announces Promotion of Richard Davis to Chief Operating Officer
May 23, 2022
Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting
May 18, 2022
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
May 17, 2022
scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX® New Drug Application
May 17, 2022
Nouscom Announces Janssen Receives U.S. FDA IND Clearance for VAC85135, an “Off-The-Shelf” Cancer Immunotherapy Developed Using Nouscom’s Proprietary Viral Vector Platform
« Previous Page
1
…
26
27
28
29
30
…
119
Next Page »